my T Cell Logo (EUIPO, 02/17/2021)
EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark my T Cell was filed as Figurative mark on 02/17/2021 at the European Union Intellectual Property Office.
It was registered as a trademark on 07/29/2021.
The current status of the mark is "Trademark registered".
Logodesign (Wiener Klassifikation)
#Armillary spheres, planetaria, astronomic orbits, atomic models, molecular models #Circles or ellipses with lines (except 26.7.3.) #One letter #Letter 'C'
| Trademark form | Figurative mark |
| File reference | 018400940 |
| Application date | February 17, 2021 |
| Publication date | April 21, 2021 |
| Entry date | July 29, 2021 |
| Expiration date | February 17, 2031 |
Trademark owner
Marchioninistraße 15
81377 München
DE
81377 München
DE
Trademark representatives
ALPHA-Haus, Garmischer Strasse 35
81373 München
DE
goods and services
9
Mobile apps to support medical and diagnostic applications in the field of cancer immunotherapy; Mobile apps to support medical and diagnostic applications in the field of bi-specific T-cell engagers and CAR T-cell therapy; Mobile apps for monitoring and treatment of toxicity released by bi-specific T-cell engagers and CAR T-cell therapy; Mobile apps for training specialised medical personnel; Mobile apps for training specialised medical personnel in the field of cancer immunotherapy, in particular in the field of bi-specific T-cell engagers and CAR T-cell therapy; Mobile apps for evaluating, monitoring and managing medical data, in particular medical data relating to the treatment of toxicity released by bi-specific T-cell engagers and CAR T-cell therapy; Mobile apps for medical and diagnostic purposes, namely for use in transferring data from medical devices to electronic data management systems; Mobile apps for creating and exchanging a disease journal and a connection to external databases and apparatus for the aforesaid; Computer software to support medical and diagnostic applications in the field of cancer immunotherapy; Computer software to support medical and diagnostic applications in the field of bi-specific T-cell engagers and CAR T-cell therapy; Computer software for monitoring and treatment of toxicity released by bi-specific T-cell engagers and CAR T-cell therapy; Computer software for training specialised medical personnel; Computer software for training specialised medical personnel in the field of cancer immunotherapy, in particular in the field of bi-specific T-cell engagers and CAR T-cell therapy; Computer software for evaluating, monitoring and managing medical data, in particular medical data relating to the toxicity released by treatment with bi-specific T-cell engagers and CAR T-cell therapy; Computer software for medical and diagnostic purposes, namely, for use in transferring data from medical devices to electronic data management systems; Computer software for creating and exchanging a disease journal and a connection to external databases and apparatus for the aforesaid
38
Providing of access to a medical care system by means of a mobile app; Providing of access to a medical care system by means of computer software; Providing of access to platforms and portals on the internet in the field of medicine, In particular in the field of bi-specific T-cell engagers and CAR T-cell therapy; Providing of access to information on the internet and other data networks in the field of medicine, In particular in the field of bi-specific T-cell engagers and CAR T-cell therapy and toxicity released by bi-specific T-cell engagers and CAR T-cell therapy; Providing of access to mobile apps and computer programs in data networks for training specialised medical personnel and patients relating to bi-specific T-cell engagers and CAR T-cell therapy and toxicity released by bi-specific T-cell engagers and CAR T-cell therapy; Providing of access to programs and databases for exchanging information among users of a computer network (online forum) in the field of health and medicine, In particular in the field of bi-specific T-cell engagers and CAR T-cell therapy and toxicity released by bi-specific T-cell engagers and CAR T-cell therapy
44
Medical services; Telemedicine services; Medical consultations
ID: 11018400940